Leerink reduced 2024 estimates for Eli Lilly to reflect incretin franchise revisions based upon prescription trends and the previously announced research and development charge. The firm says higher Mounjaro and Zepbound sales were more than offset by lower Trulicity sales. Although the firm anticipates “marginal” Q1 downside and notes that both Mounjaro and Zepbound script trends “have rolled over” in recent weeks due to supply constraints, it expects “compelling” tirzepatide Phase 3 sleep apnea results near-term. Leerink assumes that recent Mounjaro and Zepbound trends revert to growth, but adds “it is difficult to predict forthcoming weekly performance.” The firm keeps an Outperform rating on Lilly shares with an $821 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Drugmakers look to alternative suppliers after draft U.S. legislation, FT says
- Roche announces U.S. FDA granted BDD to its Elecsys pTau217 assay
- Amphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of Opportunity
- Eli Lilly sees Q1 pre-tax IPR&D charges of roughly $111M
- Viking Therapeutics Stock (NASDAQ:VKTX): Analysts Stay Bullish on 2024’s Top Mid-Cap